Enteropatía crónica felina y linfoma alimentario de bajo grado
Feline inflammatory bowel disease (IBD), Lymphoplasmacytic enteritis (LPE), Low-grade intestinal T-cell lymphoma (LGITL), Low-grade alimentary lymphoma (LGAL), Small-cell gastrointestinal lymphoma, Food-responsive enteropathy, Chronic small-bowel disease of cats
La enteropatía crónica significa que el revestimiento del intestino de su gato ha estado irritado o inflamado durante semanas o meses. Eso provoca vómitos, heces blandas, pérdida de peso o cambios en el apetito que vuelven una y otra vez. Lo complicado es que la inflamación común y un cáncer de crecimiento lento llamado linfoma de bajo grado se ven casi iguales en los análisis de sangre, las radiografías y el ultrasonido, así que la única manera de distinguirlos es tomar una muestra de tejido (una biopsia) con anestesia. En la mayoría de los gatos esto no es una emergencia, salvo que aparezca alguna de las señales de alarma que se enumeran más abajo: esas requieren una llamada el mismo día. Las dos versiones suelen poder tratarse durante mucho tiempo: en el grupo tratado más grande que se ha publicado, la mitad de los gatos seguían vivos alrededor de dos años después del diagnóstico (supervivencia mediana de 704 días), y a los gatos cuya enfermedad entró en remisión completa les fue mejor que eso. Por eso vale la pena llegar al diagnóstico correcto. Tres reglas mientras avanzan con esto. Primera: nunca le dé a su gato un medicamento humano para el dolor o la fiebre. El ibuprofeno, el naproxeno, la aspirina y el acetaminofén/paracetamol (Tylenol, Panadol) son peligrosos en gatos, y el acetaminofén/paracetamol puede matar a un gato con una sola dosis casera. Segunda: nunca le dé a su gato un medicamento que fue recetado para un perro o para otra mascota; los antiinflamatorios (AINE) para perros en particular pueden ser mortales en un gato, y las dosis no son intercambiables entre especies. Tercera: si algún medicamento para esta enfermedad se administra en casa, llame a la clínica antes de empezar, suspender, saltar, partir o cambiar la dosis de cualquier cosa, incluso 'solo por unos días', porque varios de los medicamentos que se usan aquí requieren control de los recuentos sanguíneos y una reducción gradual planificada.
Qué podría notar
- Vómitos que se repiten durante semanas o meses, a veces con pelo o comida sin digerir
- Heces blandas o diarrea que dura más de tres semanas, o que aparece y desaparece
- Pérdida de peso lenta, aunque su gato parezca comer normalmente
- Un cambio grande en el apetito en cualquier dirección: de pronto con mucha hambre, o apenas probando la comida
- Pérdida de músculo en el lomo y las caderas, de modo que la columna y los huesos se sienten más filosos
- Menos energía, dormir más, esconderse o acicalarse menos de lo habitual
- Ruidos en la barriga, gases, o un abdomen que se ve más lleno que antes
- Picazón en la piel o lamerse en exceso al mismo tiempo que los problemas digestivos
- Señales de náusea: babeo, lamerse los labios, tragar en seco, o quedarse encorvado frente al bebedero sin beber
Estándar de atención
- Esta sección aún no está disponible en español.
Descarte primero las condiciones que la imitan, antes de cualquier medicamento a largo plazo
Aprobado / respaldado por guíasFull physical exam, CBC, biochemistry, total T4, FeLV/FIV status, faecal parasitology, urinalysis, and serum cobalamin plus folate. Abdominal ultrasound to assess wall layering, wall thickness and the jejunal lymph nodes. Imaging narrows the differential but cannot make the diagnosis. IMPORTANT CAVEAT ON T4: a total T4 inside the reference interval does NOT exclude hyperthyroidism in this population. Non-thyroidal illness lowers total T4 - mean serum total T4 was significantly lower in 98 sick cats with nonthyroidal illness (17.18 +/- 8.14 nmol/L) than in 50 healthy cats (26.00 +/- 7.62 nmol/L), P<0.001 - so a mid-range total T4 in a thin, chronically unwell older cat is uninterpretable on its own. If the clinical picture fits, repeat the total T4 and add free T4 by equilibrium dialysis together with TSH; free T4 must not be used as a sole criterion, because a few sick euthyroid cats in that same study had free T4 above the reference range.
Productos nombrados: No drug at this step.
The 2023 ACVIM consensus statement concludes that 'no single diagnostic criterion or known biomarker reliably differentiates inflammatory lesions from neoplastic lymphoproliferations in the intestinal tract of cats and a diagnosis currently is established by integrating all available clinical and diagnostic data.' On thyroid testing: prospective study of 98 cats with nonthyroidal illness vs 50 clinically normal cats, total T4 by radioimmunoassay and free T4 by direct equilibrium dialysis.
- Esta sección aún no está disponible en español.
Haga una prueba dietética estricta de eliminación — es la intervención de mayor rendimiento y no conlleva riesgo farmacológico
Ensayo controlado en esta especieA commercial selected-protein, novel-protein or hydrolysed diet, fed exclusively: no treats, no flavoured medications, no other household cat's food. Re-challenge with the previous diet afterwards to confirm. Roughly half of cats with chronic idiopathic GI signs respond to diet alone. ON DURATION: the 2023 ACVIM consensus statement specifies no dietary-trial duration for cats, so the window here is anchored on Laflamme 2011 instead - clinical improvement was noted within the first week and maximised within 3 weeks, and the authors conclude that 'cats that do not respond within 3 weeks should be evaluated further'. A 2-4 week trial is therefore reasonable, with a hard re-evaluation point at 3 weeks. ON DIET TYPE: the 29%/20% food-sensitivity figures come from a study that used commercial SELECTED-PROTEIN diets (Guilford 2001), not hydrolysed diets, which were not in routine feline use in 2001; we have no feline chronic-enteropathy trial comparing hydrolysed against selected-protein diets, so do not claim one type is superior. ABORT CONDITION - STATE THIS TO EVERY OWNER: a cat that will not eat the trial diet at all within 24-48 hours must come off the trial and be reassessed. An already thin or inappetent cat put on a single exclusive novel food it refuses can be in hepatic lipidosis within days; calorie intake outranks diet purity every time.
Productos nombrados: Diet only. No named drug.
In 55 cats with chronic idiopathic gastrointestinal signs, 16 (29%) were diagnosed food-sensitive on dietary elimination-challenge using commercial selected-protein diets, and a further 11 (20%) resolved on the elimination diet but did not relapse on challenge. Diagnosis could NOT be made from clinical signs, routine clinicopathology, serum antigen-specific IgE, gastroscopic food sensitivity testing, or GI biopsy - only from the trial itself. Separately, a randomised, double-blinded, controlled clinical trial in 60 cats with chronic diarrhoea (55 completed) found faecal scores improved significantly in 78.2% of cats, with over a third developing normal stools; dietary fat content did not affect outcome; improvement began within 1 week and maximised within 3 weeks.
- Esta sección aún no está disponible en español.
Mida y corrija la cobalamina (vitamina B12)
Ensayo controlado en esta especieHypocobalaminaemia is common in feline small-bowel disease and contributes to inappetence and weight loss. In a retrospective series of 25 cats with serum cobalamin at or below 250 pmol/L and clinical signs of chronic enteropathy, 0.25 mg cyanocobalamin tablets once daily raised serum cobalamin above the reference interval in all 25 cats. Read that result honestly: the endpoint reached was SUPRAPHYSIOLOGIC, not merely normal - median serum cobalamin rose from 128 pmol/L (range 111-250) to 2701 pmol/L (range 738-16,359) against a reference interval of 214-738 pmol/L (P<0.0001). Serum cobalamin was rechecked 27-94 days after continuous oral supplementation, so that is the interval to plan for. The authors' own conclusion is that oral supplementation is 'a promising alternative to parenteral administration' and that 'prospective comparative studies in cats being treated with parenteral vs oral cobalamin supplementation in a larger number of patients are warranted before oral supplementation can be recommended for routine use'. Do not present the oral route as established equivalence.
Productos nombrados: Cyanocobalamin 0.25 mg tablets PO q24h was the regimen studied. No FDA NADA for a feline chronic-enteropathy indication was located; this is extralabel use on a veterinarian's order within a valid VCPR. Dosing, and any switch between the oral and injectable route, is a veterinary decision - do not change the route or stop supplementing at home without calling.
Retrospective single-centre series, n=25 cats, oral route, recheck at 27-94 days; 78% of tested cats in a separate 41-cat low-grade lymphoma series had low serum cobalamin, establishing how often this needs checking. The 2023 ACVIM consensus statement also notes hypocobalaminaemia was significantly more prevalent in cats with LGITL than LPE, with reported prevalence ranging from 18% to 80% across studies.
- Esta sección aún no está disponible en español.
Haga biopsia antes de comprometerse con inmunosupresión o quimioterapia a largo plazo
Aprobado / respaldado por guíasEndoscopic or full-thickness surgical biopsy with histopathology plus immunohistochemistry, and clonality testing where available. Full-thickness biopsy reaches jejunum and ileum that endoscopy cannot, at the cost of a laparotomy. The consensus panel explicitly cautions against reclassifying a cat previously diagnosed with IBD as lymphoma on the basis of clonality testing alone: 'clinicians should refrain from reclassification of cases based on clonality results alone.' FRAME THE ANAESTHETIC AND SURGICAL RISK EXPLICITLY, DO NOT ASSUME IT: the typical patient here is roughly 8 years old, underweight, often losing muscle and sometimes hypoalbuminaemic, and general anaesthesia in that patient is not a formality. The two biopsy routes do not carry the same risk - endoscopy is less invasive but samples only the reachable proximal gut and only the mucosa, while full-thickness surgical biopsy samples the segments endoscopy misses and carries an incision that has to heal, with dehiscence a recognised concern in a hypoalbuminaemic cat. Which route, and whether the cat is stable enough today, is a case-by-case veterinary decision that belongs in an informed-consent conversation covering anaesthetic risk, the alternative of treating empirically without a diagnosis, and what each choice costs.
Productos nombrados: No drug at this step. General anaesthesia is required; there is no non-invasive substitute, and no product PetSmartMeds sells may be positioned as one.
ACVIM consensus 2023: histopathology remains the mainstay for differentiating LPE from LGITL; most panel recommendations rest on a moderate or low level of evidence, and few prospective studies exist. Paulin 2018: 'A combination of conventional histopathology and immunohistochemistry remains the current gold-standard test.' Note that in the largest chlorambucil series, 24 of 28 cats were diagnosed on full-thickness rather than endoscopic biopsy (Stein 2010).
- Esta sección aún no está disponible en español.
Enteropatía crónica inflamatoria (LPE): prednisolona, reducida hasta la dosis mínima eficaz — y nunca prednisona
Ensayo controlado en esta especiePrednisolone 1-2 mg/kg PO q24h, then tapered according to clinical response, was the active comparator in a small randomised, owner-blinded trial (n=6 per arm, no placebo arm). DOSE ON LEAN OR IDEAL BODY WEIGHT, AND HERE IS WHY: in an 11-cat two-drug crossover study, over-conditioned cats reached approximately 2-fold higher plasma drug concentrations than normal-conditioned cats, which the authors say 'might explain their perceived increased risk for glucocorticoid associated side effects (hepatic lipidosis, diabetes mellitus)'. Dosing a fat cat on scale weight is therefore a real overdose, not a rounding error. Prednisone must not be substituted for prednisolone in cats: in the same study a single 2 mg/kg oral dose of prednisolone produced roughly 4-fold higher plasma prednisolone AUC than the same dose of prednisone. FELINE GLUCOCORTICOID RISK PROFILE, WHICH MUST BE DISCUSSED BEFORE THE FIRST DOSE: (1) diabetes mellitus - cats are notably prone to glucocorticoid-associated diabetes, and the authors of the crossover study name it as one of the two side effects over-dosing predisposes to; monitor water intake, urine volume and blood/urine glucose. (2) Congestive heart failure in a cat with occult cardiac disease - in 12 cats given methylprednisolone acetate, plasma volume increased by 13.4% (more than 40% in 3 of the 12) via a glucocorticoid-mediated hyperglycaemic fluid shift, and the authors conclude that 'any cardiovascular disorders that impair the normal compensatory mechanisms for increased plasma volume may predispose cats to CHF'. Auscultate before starting, and treat any new tachypnoea or dyspnoea on steroids as urgent. (3) Do not stop abruptly after prolonged therapy - taper on veterinary instruction. (4) The human prednisolone label's contraindication is systemic fungal infections and hypersensitivity; the label also warns that corticosteroids suppress the immune system and increase the risk of infection with any pathogen, can mask signs of infection, and that immunisation procedures should not be undertaken in patients on corticosteroids. Do not vaccinate a cat during immunosuppressive therapy without veterinary direction, and do not add an NSAID.
Productos nombrados: Prednisolone (oral, human-labelled). No FDA NADA and no EMA marketing authorisation for a feline chronic-enteropathy indication was located in this research; use for this indication is extralabel under 21 CFR 530.30 and lawful only by or on the lawful order of a licensed veterinarian within a valid VCPR. Do NOT substitute prednisone. Human-label contraindications: systemic fungal infections; hypersensitivity. Never stop abruptly; never dose on scale weight in an over-conditioned cat; call the clinic before any dose change at home.
Prednisolone 1-2 mg/kg q24h tapered to response served as the active comparator in a randomised, owner-blinded trial (n=6 per arm, no placebo arm) and produced a mean FCEAI of 3.7 at six months from a pretreatment mean of 3.6. Feline prednisone/prednisolone pharmacokinetics: two-drug crossover in 11 cats (5 normal-conditioned, 6 over-conditioned), HPLC plasma concentrations, ~4-fold higher AUC for prednisolone and ~2-fold higher concentrations in over-conditioned cats. Glucocorticoid haemodynamics: repeated-measures study in 12 cats given methylprednisolone acetate 5 mg/kg IM, with plasma volume and total body water measured at baseline, 3-6 days and 16-24 days.
- Esta sección aún no está disponible en español.
Linfoma alimentario de bajo grado (LGITL/LGAL): clorambucilo más un glucocorticoide
Ensayo controlado en esta especieThis is the best-supported protocol in feline oncology for this disease, and the response durations are long. Dosing protocols are not standardised across the literature; the pharmacokinetic study that informs current practice used a 2 mg total oral dose given every other day, which showed rapid absorption, a terminal half-life of 1.8 h, and no accumulation between doses in 24 cats. WHICH GLUCOCORTICOID THE EVIDENCE ACTUALLY USED - DO NOT LET THIS BE SILENTLY SUBSTITUTED: the 41-cat series used PREDNISONE ('treated with prednisone and chlorambucil'), and the 28-cat series reports only 'glucocorticoids' without naming the agent. Prednisolone is preferred in cats on pharmacokinetic grounds (Center 2013, ~4-fold higher AUC than prednisone), but the published outcome data for this protocol were not generated with prednisolone, and this page will not pretend otherwise. MONITORING FLOOR, NOT OPTIONAL: CBC before the first dose, then serially - conventionally every 2-4 weeks during induction and every 1-3 months once stable - with a urine dipstick for glucose at each CBC. The human chlorambucil label states that most patients develop some neutropenia after the third week and that the fall in neutrophil count 'may continue for 10 days after the last dose'; that the dose 'should be decreased if leukocyte or platelet counts fall below normal values and should be discontinued for more severe depression'; and that as cumulative dose approaches 6.5 mg/kg in one course there is a risk of irreversible bone marrow damage. A neutropenic cat stops dosing and is reassessed - that decision is the veterinarian's, made on a current CBC, not on how the cat looks. SECOND MALIGNANCY: four of the 28 cats in the chlorambucil series were subsequently diagnosed with a second malignancy, which is consistent with the human boxed warning that chlorambucil 'is a carcinogen in humans'. Disclose this before starting, not after.
Productos nombrados: Chlorambucil (human-labelled alkylating agent, marketed as Leukeran) plus a glucocorticoid - prednisolone in a cat, with the evidence caveat above. No FDA NADA for any feline indication was located in this research; veterinary use is extralabel use of an approved human drug under 21 CFR 530.30, lawful only by or on the lawful order of a licensed veterinarian within a valid VCPR. LEUKERAN BOXED WARNING, VERBATIM: 'LEUKERAN (chlorambucil) can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility.' Human-label contraindications: prior demonstrated resistance to the agent; hypersensitivity to chlorambucil (with possible cross-hypersensitivity to other alkylating agents). The label also warns of convulsions and secondary malignancies including acute leukaemia, with risk rising with duration and cumulative dose and no cumulative dose below which risk is absent, and cautions in patients with a history of seizures. Chlorambucil is cytotoxic and requires household handling precautions - see safety.
28 cats (24 with full-thickness biopsies) with small-cell GI lymphoma treated with chlorambucil plus glucocorticoids: overall clinical response rate 96%, median clinical remission duration 786 days; 7 cats relapsed and all 7 responded to a rescue protocol of cyclophosphamide PLUS glucocorticoids (response rate 100%); and 4 of the 28 cats were diagnosed with a second malignancy. Separately, 41 cats with low-grade lymphocytic lymphoma of various organ systems on prednisone plus chlorambucil: 56% complete response, 39% partial response, 5% no response - i.e. 95% overall response; median remission 897 days after complete response vs 428 days after partial response; overall median survival 704 days. Both are retrospective, single- or few-centre series with no control arm. The honest summary is an overall clinical response of 95-96% across the two series, with complete response in 56% of the 41-cat series - not a '56-96%' range, which would splice a complete-response floor onto an overall-response ceiling.
- Esta sección aún no está disponible en español.
LGAL recaído: ciclofosfamida más glucocorticoides como primer rescate
Ensayo controlado en esta especieFor cats that relapse after chlorambucil, cyclophosphamide - given with a glucocorticoid, which is how both published feline experiences used it - is the best-documented first rescue option. CYCLOPHOSPHAMIDE-SPECIFIC TOXICITY THAT MUST BE ON THE PAGE: the signature adverse effect of this drug class is urothelial. The human label states that 'hemorrhagic cystitis, pyelitis, ureteritis, and hematuria have been reported with cyclophosphamide' and that 'urotoxicity can be fatal', and the drug is CONTRAINDICATED in urinary outflow obstruction - so any urinary obstruction must be excluded or corrected before treatment. Blood in the urine, or straining and frequent small urinations, on cyclophosphamide is a call-before-the-next-dose event, and it is exactly the sign an owner will otherwise misfile as constipation. Encourage water intake and do not let a cat hold urine overnight after dosing. MYELOSUPPRESSION FLOOR: the human label states that 'monitoring of complete blood counts is essential during cyclophosphamide treatment' and that the drug should not be administered at neutrophils <=1,500/mm3 and platelets <50,000/mm3; the leukocyte and platelet nadirs are usually reached in weeks 1-2. The 20-cat feline rescue series reported adverse events that were few and reversible (constitutional, gastrointestinal and haematologic) and did NOT report cystitis - which is reassuring but is 20 retrospective cats, not a safety clearance, and does not displace the label.
Productos nombrados: Cyclophosphamide (human-labelled) plus a glucocorticoid. Extralabel use of an approved human drug under 21 CFR 530.30, lawful only by or on the lawful order of a licensed veterinarian within a valid VCPR; no FDA NADA for a feline LGAL indication was located. Human-label contraindications: hypersensitivity to cyclophosphamide or its metabolites (anaphylaxis including death reported; cross-sensitivity with other alkylating agents can occur) and URINARY OUTFLOW OBSTRUCTION. Human-label warnings include myelosuppression and fatal infection, urinary tract and renal toxicity, cardiotoxicity including congestive heart failure, pulmonary toxicity, secondary malignancies, veno-occlusive liver disease and embryo-fetal toxicity. Cytotoxic - the same household handling precautions as chlorambucil apply.
20 cats across three institutions with clinically presumed relapsed LGAL after failing chlorambucil: 18/20 (90%) achieved a complete clinical response for a median 239 days; median progression-free survival 215 days; median overall survival time 1065 days; adverse events were few and reversible. Retrospective, no control arm. In the separate 28-cat chlorambucil series, all 7 relapsed cats responded to a rescue protocol of cyclophosphamide and glucocorticoids (100%).
- Esta sección aún no está disponible en español.
Apoyo nutricional y manejo del apetito mientras se controla la enfermedad primaria
Aprobado / respaldado por guíasWeight, body condition score and muscle condition score at every visit. Address inappetence early rather than waiting; assisted feeding, including a feeding tube, is appropriate where a cat will not maintain intake, and the ISFM panel is explicit that postponing tube placement to await improvement may hinder recovery. Cats that stop eating are at risk of hepatic lipidosis. THE ONE SPECIES-APPROVED DRUG ON THIS PAGE: mirtazapine transdermal ointment (MIRATAZ, NADA 141-481, Dechra Veterinary Products) is FDA-approved in CATS, with the indication 'for body weight gain in cats with a history of weight loss'. That indication maps onto the purpose of this step, but note precisely what it is and is not: it is an approval for weight gain in cats generally, NOT an approval for feline chronic enteropathy, low-grade alimentary lymphoma, or any gastrointestinal indication, and using it as part of an enteropathy plan is still off-indication use decided by the prescribing veterinarian. Label limits: cats only; not evaluated in cats under 6 months of age or under 2 kg; contraindicated with hypersensitivity to mirtazapine and with monoamine oxidase inhibitors, including within 14 days before or after MAOI treatment, because of serotonin syndrome risk. It is applied to the inner ear; wear disposable gloves, dispose of them after each application, wash hands with soap and water, and avoid contact with the treated cat for 2 hours - it is a transdermal product, so a person who pets the cat is a potential exposure. WHY ELURA IS DELIBERATELY NOT NAMED HERE: capromorelin oral solution (ELURA, NADA 141-536, Elanco US Inc.) is also cat-only and also an appetite/weight drug, but its approved indication is narrower - 'for management of weight loss in cats with chronic kidney disease' - so it does not fit this indication; its label also warns against use in cats with hypersomatotropism and in cats with current or historical diabetes mellitus, and notes it may increase serum glucose for several hours after dosing. That omission is a decision, not a gap.
Productos nombrados: Mirtazapine transdermal ointment (MIRATAZ, NADA 141-481, Dechra) - FDA-approved in cats for body weight gain in cats with a history of weight loss; NOT approved for chronic enteropathy or lymphoma. Cats only; not evaluated below 6 months of age or below 2 kg; contraindicated with MAO inhibitors or within 14 days of them, and with mirtazapine hypersensitivity; gloves required, avoid contact with the cat for 2 hours after application. Capromorelin (ELURA, NADA 141-536, Elanco) is intentionally NOT recommended here: its approved feline indication is restricted to weight loss in cats with chronic kidney disease. Appetite drugs do not replace calorie delivery - if the cat is not eating enough, the conversation is about assisted feeding, and it is a veterinary decision.
ISFM consensus guidelines on the management of the inappetent hospitalised cat cover assisted feeding, feeding tubes, antiemetic/analgesic/prokinetic/appetite-stimulant medication and appetite stimulation in this population, and state that delayed intervention may result in deterioration. Mirataz and Elura indications, species, age/weight limits and contraindications verified on the FDA-approved labels via DailyMed.
- Esta sección aún no está disponible en español.
Orden de las acciones — dígalo con claridad a los clientes
Aprobado / respaldado por guíasDiagnosis, diet and correctly dosed conventional drugs outperform every injectable on the evidence available today. No cell product, exosome product or peptide has ever been shown to beat prednisolone or chlorambucil in a cat, and none has been studied at all in cats with low-grade alimentary lymphoma. A biologic may only ever be discussed as an adjunct or as an option for a cat that has failed or cannot tolerate standard therapy, and only inside an informed-consent conversation. AND HERE IS THE CLINICAL REASON THE BIOPSY-FIRST RULE IS NOT BUREAUCRACY: mesenchymal stromal cells are administered for their immunomodulatory and immunosuppressive effect. The disease being treated is, until a biopsy says otherwise, indistinguishable from a T-cell lymphoproliferative disorder. Giving an immunomodulatory cell product to a cat whose undiagnosed disease is actually an active lymphoma has no evidentiary basis in any species and a coherent theoretical hazard, and neither published feline MSC study enrolled a single cat with LGITL or LGAL. That is the strongest argument on this page for biopsying before treating, and it applies to a cell product far more sharply than it applies to a diet trial.
Productos nombrados: Not applicable.
The published feline biologic evidence base for this condition totals 13 treated cats across two studies from one research group, neither of which enrolled a cat with lymphoma. By contrast the chlorambucil literature covers 28 cats with small-cell GI lymphoma (Stein 2010) plus 41 cats with low-grade lymphocytic lymphoma of various organ systems, GI-confined in 68% (Kiselow 2008) - so roughly 56 LGAL-specific cats, not 69 - with an overall clinical response of 95-96% and remission or survival durations measured in years. The contrast survives the corrected denominator easily.
ACVIM consensus statement guidelines on diagnosing and distinguishing low-grade neoplastic from inflammatory lymphocytic chronic enteropathies in cats — American College of Veterinary Internal Medicine (ACVIM)
Cómo se diagnostica
- History and physical exam focused on duration, weight trajectory, appetite direction (polyphagia is a discriminator), vomiting vs diarrhoea vs both, and concurrent dermatological signs. Ask specifically what other pets in the house are medicated with, and whether any human or canine medication has already been given.
- CBC, serum biochemistry, total T4, FeLV/FIV status, urinalysis, and faecal parasitology to exclude the treatable look-alikes.
- Do not treat a reference-interval total T4 as excluding hyperthyroidism in this population. Non-thyroidal illness suppresses total T4 (mean 17.18 +/- 8.14 nmol/L in 98 sick cats vs 26.00 +/- 7.62 nmol/L in 50 healthy cats, P<0.001), so a mid-range total T4 in a thin, chronically unwell older cat does not settle the question; repeat the total T4 and add free T4 by equilibrium dialysis together with TSH where suspicion is high, remembering that free T4 alone is not a sufficient criterion (PMID 8707673; PMID 27143042).
- Serum cobalamin and folate - hypocobalaminaemia was present in 78% of tested cats in one 41-cat low-grade lymphoma series and both guides treatment and localises disease.
- A strict hydrolysed, novel-protein or selected-protein elimination diet trial with re-challenge, BEFORE immunosuppression: 2-4 weeks with a hard re-evaluation at 3 weeks, because improvement began within 1 week and was maximal by 3 weeks in a randomised double-blinded trial of 60 cats, whose authors conclude that cats not responding within 3 weeks need further evaluation (PMID 21281349). Roughly half of cats with chronic idiopathic GI signs respond to diet, and food sensitivity cannot be diagnosed any other way - not by signs, not by serum IgE, not by biopsy (PMID 11215916). Abort and call if the cat refuses the trial diet for 24-48 hours.
- Abdominal ultrasound assessing wall thickness and layering, and specifically the jejunal lymph nodes; a rounded jejunal lymph node and small-volume abdominal effusion tended to favour LGITL over LPE. Imaging narrows, it does not decide.
- Endoscopic or full-thickness surgical biopsy with histopathology plus immunohistochemistry, and clonality testing where available - required before long-term immunosuppression or chemotherapy, and required before any cell product is even discussed. Full-thickness biopsy samples jejunum and ileum that endoscopy cannot reach; it also carries a healing incision, and dehiscence is a recognised concern in a hypoalbuminaemic cat, so the route choice and the anaesthetic risk belong in the consent conversation.
- Integrate everything rather than trusting one test: the 2023 ACVIM consensus panel found no single criterion or biomarker that reliably separates LPE from LGITL, and stated that 'clinicians should refrain from reclassification of cases based on clonality results alone.'
Dónde encaja un biológico
Nuestro propio producto, calificado con la misma regla
Respuesta corta: aquí hay evidencia preliminar. Prometedora, no probada.
En dos estudios pequeños de un solo centro y de un solo grupo de investigación —una prueba de concepto ciega y controlada con placebo en 7 gatos tratados, y una comparación aleatorizada con el dueño ciego de 6 gatos por grupo frente a prednisolona, sin grupo placebo— dos dosis intravenosas de células madre mesenquimales FELINAS derivadas de tejido adiposo mejoraron los signos clínicos de la enteropatía crónica, y la conclusión de los propios autores fue que este protocolo específico parecía ser TAN EFICAZ COMO un curso estándar de prednisolona, no superior a él; en toda la literatura felina publicada sobre estas células, 150 de 215 gatos tratados (69,8%) no tuvieron eventos adversos reportados, así que no se trata de una intervención sin riesgo; los propios autores señalan que estos resultados preliminares 'requieren un estudio de seguimiento importante' y que las evaluaciones actuales siguen estando en su mayoría en fase de descubrimiento; no se ha publicado ningún ensayo multicéntrico ni controlado con placebo; nunca se ha incluido a un gato con linfoma alimentario de bajo grado, y dar un producto celular inmunomodulador a un gato cuyo linfoma no está diagnosticado es un riesgo teórico concreto, no una opción neutra; ningún producto de exosomas ni de péptidos tiene evidencia publicada de eficacia in vivo en gatos con enfermedad digestiva; y no existe ningún producto celular ni de exosomas aprobado por la FDA para ningún uso en gatos.
Qué existe
Esta sección aún no está disponible en español.FELINE ADIPOSE-DERIVED MSC, LIVE CELLS, INTRAVENOUS - two small studies, one research group (Colorado State University), both in cats with non-neoplastic chronic enteropathy. LEAD WITH THE AUTHORS' OWN CONCLUSION, WHICH IS EQUIVALENCE, NOT SUPERIORITY: 'this specific fMSC protocol appears to be as effective in the treatment of feline IBD as a standard course of prednisolone therapy' (Webb & Webb 2022). (1) Blinded, placebo-controlled proof-of-concept: 7 cats with diarrhoea of at least 3 months' duration received allogeneic adipose-derived feline MSC (fMSC) and 4 received placebo, blinded, with no diet or medication changes during the study; 3 further cats were treated open-label. No adverse reactions or side effects were attributed to fMSC in any cat IN THAT 11-CAT STUDY - see the safety framing below before generalising that. Owners of 5/7 fMSC cats reported significant improvement or complete resolution; the other 2 reported modest but persistent improvement; owners of placebo cats reported no change or worsening. The authors state 'these preliminary results require significant follow-up study.' Webb TL, Webb CB. J Feline Med Surg. 2015;17(10):901-8. PMID 25480816. DOI 10.1177/1098612X14561105. (2) Randomised, owner-blinded, active-comparator trial with NO placebo arm: cats that failed a 2-week diet trial and had endoscopic-biopsy-confirmed IBD were randomised to fMSC (two IV injections of 2 x 10^6 freshly cultured allogeneic cells/kg, 14 days apart) or prednisolone 1-2 mg/kg PO q24h tapered to response; 6 per arm completed and one cat in each arm failed at the 2-month recheck. At 6 months mean FCEAI was 3.7 (range 0.5-9) for prednisolone vs 0.75 (range 0-1.5) for fMSC, from near-identical pretreatment means of 3.6 and 3.7 - and that numerical difference must never be reported without the following limitations in the same breath, because n=6 per arm with no placebo arm cannot support a comparative-efficacy claim: 6 cats per arm, single centre, no placebo arm, baseline mean body weight differed between arms (3.6 vs 4.9 kg), sex distribution differed between arms (all six prednisolone cats were spayed females; the fMSC arm was three female and three male), owners were blinded but investigator blinding is not stated, and the authors' stated conclusion is equivalence. PetSmartMeds will not present '0.75 versus 3.7' as a superiority finding, and will not present it at all in owner-facing copy: presenting a numerical comparative-efficacy result for an unapproved cell product is, in substance, an efficacy claim for an unapproved new animal drug. SAFETY MUST BE STATED AT FIELD SCALE, NOT AT 11-CAT SCALE: the same authors' 2024 scoping review of the entire feline MSC literature reports that 'the majority (150/215 [69.8%]) of cats had no reported adverse events associated with treatment' - which means roughly 30% of the 215 treated cats across the published feline literature either experienced an adverse event or had none reported, and that is the number to quote, attributed, rather than an absolute zero-event line from a single 11-cat study. Context on the whole feline field from the same review: 108 publications, of which 26 administered MSC to 215 cats; only 12 studies had a control group; 7 cell sources, 9 administration routes, 12 delivery vehicles and a 300-fold dosage range; median 6.5 treated cats per study monitored for a median of 90 days; and the authors conclude that 'current evaluations are mostly still in the discovery phase' and that 'no approved stem cell products are available for use in cats in the US' (Webb TL, Webb CB. Scoping review of the use of mesenchymal stem and stromal cell products in cats, Part 1: current logistics and safety. J Am Vet Med Assoc. 2024;262(S1):S16-S23. PMID 38565136. DOI 10.2460/javma.24.02.0074; Part 2: current scope and efficacy. 2024;262(S1):S24-S30. PMID 38565137. DOI 10.2460/javma.24.02.0080 - both titles and PMIDs verified in this pass). Everything else in this space is an induced model or a rodent: a DSS-induced feline IBD model treated with MSC (Xie Q, et al. Stem Cell Res Ther. 2024. DOI 10.1186/s13287-024-04038-y) and DSS colitis in MICE treated with feline-derived MSC or their PGE2 (An JH, et al. BMC Vet Res. 2018. DOI 10.1186/s12917-018-1684-9; Kim H, et al. J Vet Sci. 2023. DOI 10.4142/jvs.23106). Induced-model and mouse data are not feline clinical evidence and must never be presented as such.
Qué no se ha demostrado
Esta sección aún no está disponible en español.1. NO exosome or extracellular-vesicle evidence of any kind in cats with gastrointestinal disease. There is no published in-vivo efficacy study of any exosome or EV preparation in a cat or a dog with chronic enteropathy, IBD, or alimentary lymphoma. The single best-designed in-vivo companion-animal EV trial located anywhere in the literature is a 30-cat randomised study in limbal stem cell deficiency, with steroid treatment as the comparator - an OCULAR indication with no bearing on the gut, and with one author affiliated to a commercial exosome company (EXONOID Biotechnology, Inc.), which should be disclosed whenever it is cited (Ergin I, et al. Vet Res Commun. 2025;49(6):349. PMID 41055800. DOI 10.1007/s11259-025-10908-4). 2. NO peptide evidence. Searches for BPC-157, TB-500, KPV, LL-37 and GHK-Cu in cats with chronic enteropathy returned no controlled efficacy study in any companion-animal species. BPC-157 has exactly one genuine veterinary record and it is beagle pharmacokinetics with no efficacy endpoint of any kind: elimination half-life under 30 minutes, intramuscular bioavailability 45-51% in beagle dogs (He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. PMID 36588717. DOI 10.3389/fphar.2022.1026182). KPV and BPC-157 have rodent colitis data only; rodent colitis is not feline chronic enteropathy. TB-500 is banned by the FEI. 3. NO biologic evidence in low-grade alimentary lymphoma, and a specific hazard in offering one. Neither feline MSC study enrolled a cat with LGITL or LGAL. Treating a T-cell lymphoproliferative disorder with an immunomodulatory, immunosuppressive cell product has no evidentiary basis and a coherent theoretical hazard - and because LPE and LGITL are indistinguishable without biopsy, any cat offered a cell product before biopsy is a cat that might have an undiagnosed lymphoma. Biologics must not be offered for the lymphoma arm of this disease, and must not be offered as a way to skip the biopsy. 4. NO xenogeneic evidence in the feline gut. There is no study of equine or human umbilical-cord MSC or their derivatives in cats with GI disease. Carrying the DogStem result across does not work: DogStem (EMA EMEA/V/C/005829) is authorised by the EUROPEAN MEDICINES AGENCY - it holds no FDA approval - for canine OSTEOARTHRITIS in DOGS using EQUINE umbilical-cord MSC, and reported 51% of treated dogs vs 5% of placebo meeting a force-plate gait endpoint at 8 weeks. Different species, different tissue, different disease, different regulator. 5. 'IMMUNE-PRIVILEGED' IS NOT A DEFENSIBLE CLAIM and we will not publish it, nor any 'zero-flare' equivalent. In a randomised controlled safety trial of 24 young healthy police working dogs given intra-articular xenogeneic equine umbilical-cord MSC, allogeneic canine adipose MSC or placebo 1:1:1, no adverse events were detected after single or repeated administration BUT, in the authors' own words, 'both equine and canine MSC generate antibody titres in the dogs' (Punzon E, Garcia-Castillo M, Rico MA, Padilla L, Pradera A. Local, systemic and immunologic safety comparison between xenogeneic equine umbilical cord mesenchymal stem cells, allogeneic canine adipose mesenchymal stem cells and placebo: a randomized controlled trial. Front Vet Sci. 2023;10:1098029. PMID 37266387. DOI 10.3389/fvets.2023.1098029 - note all but one author are employed by EquiCord S.L., the DogStem manufacturer; disclose this whenever citing it). These products are not immune-invisible, and the finding holds for the allogeneic route as well as the xenogeneic one. 6. NO APPROVED PRODUCT. In the United States no animal cell-, tissue- or exosome-based product is FDA-approved for any species or indication; such products are unapproved new animal drugs. FDA has enforced against conditioned media - the upstream material from which exosome preparations are made - as an unapproved new animal drug, and FDA's 2019 public safety notification states plainly that 'there are currently no FDA-approved exosome products.' Separately, 21 CFR 530.4 prohibits advertising or promoting extralabel uses even of lawfully approved drugs, so 'educational content' that functions as extralabel promotion is extralabel promotion.
Fuentes
- Feline MSC proof-of-concept in chronic enteropathy, n=7 treated, blinded, placebo-controlled — Webb TL, Webb CB. Stem cell therapy in cats with chronic enteropathy: a proof-of-concept study. J Feline Med Surg. 2015;17(10):901-8. PMID 25480816. DOI 10.1177/1098612X14561105 https://doi.org/10.1177/1098612X14561105
- Feline MSC vs prednisolone in biopsy-confirmed IBD, randomised, n=6 per arm, no placebo arm; authors' conclusion is equivalence, not superiority — Webb TL, Webb CB. Comparing adipose-derived mesenchymal stem cells with prednisolone for the treatment of feline inflammatory bowel disease. J Feline Med Surg. 2022;24(8):e244-e250. PMID 35713592. DOI 10.1177/1098612X221104053 https://doi.org/10.1177/1098612X221104053
- Scoping review Part 1 - feline MSC logistics and SAFETY; the 150/215 (69.8%) no-adverse-event figure and 'no approved stem cell products... in the US' — Webb TL, Webb CB. Scoping review of the use of mesenchymal stem and stromal cell products in cats, Part 1: current logistics and safety. J Am Vet Med Assoc. 2024;262(S1):S16-S23. PMID 38565136. DOI 10.2460/javma.24.02.0074 https://doi.org/10.2460/javma.24.02.0074
- Scoping review Part 2 - feline MSC scope and EFFICACY; 192 cats across 24 publications, mostly uncontrolled, outcomes from no response to long-term cure — Webb TL, Webb CB. Scoping review of the use of mesenchymal stem and stromal cell products in cats, Part 2: current scope and efficacy. J Am Vet Med Assoc. 2024;262(S1):S24-S30. PMID 38565137. DOI 10.2460/javma.24.02.0080 https://doi.org/10.2460/javma.24.02.0080
- Both allogeneic AND xenogeneic MSC raised antibody titres in HEALTHY dogs - why 'immune-privileged' is not publishable — Punzon E, Garcia-Castillo M, Rico MA, Padilla L, Pradera A. Local, systemic and immunologic safety comparison between xenogeneic equine umbilical cord mesenchymal stem cells, allogeneic canine adipose mesenchymal stem cells and placebo: a randomized controlled trial. Front Vet Sci. 2023;10:1098029. PMID 37266387. DOI 10.3389/fvets.2023.1098029. n=24 young healthy police working dogs, intra-articular, 1:1:1. No adverse events; 'both equine and canine MSC generate antibody titres in the dogs'. Author conflict: EquiCord S.L. (DogStem manufacturer). https://doi.org/10.3389/fvets.2023.1098029
- Best in-vivo companion-animal exosome trial located - CATS, but an OCULAR indication, not gastrointestinal; commercial author affiliation — Ergin I, Sainkaplan S, Isik M, Cinar OO, Bayraktaroglu AG, Derkus B, Senel OO. Therapeutic effects of adipose mesenchymal stem cell-derived exosomes on limbal stem cells deficiency in cats. Vet Res Commun. 2025;49(6):349. PMID 41055800. DOI 10.1007/s11259-025-10908-4. n=30 cats with severe conjunctivalization randomised to steroid (n=15) or feline adipose MSC-derived exosomes (n=15). One author affiliated with EXONOID Biotechnology, Inc. https://doi.org/10.1007/s11259-025-10908-4
- Only genuine BPC-157 veterinary record - beagle pharmacokinetics, no efficacy endpoint in any species — He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. PMID 36588717. DOI 10.3389/fphar.2022.1026182 https://doi.org/10.3389/fphar.2022.1026182
- FDA: no approved exosome products (human-side notification; the veterinary-side position is that no animal cell/tissue product is FDA-approved) — FDA. Public Safety Notification on Exosome Products, 6 December 2019. https://www.fda.gov/vaccines-blood-biologics/safety-availability
Seguimiento de la respuesta
Cómo saber si está funcionando
Los clínicos lo siguen con Feline Chronic Enteropathy Activity Index (FCEAI).
Jergens AE, Crandell JM, Evans R, Ackermann M, Miles KG, Wang C. A clinical index for disease activity in cats with chronic enteropathy. J Vet Intern Med. 2010;24(5):1027-33. PMID 20584141. DOI 10.1111/j.1939-1676.2010.0549.x. Developed in 82 cats: retrospective review of 59 cats with IBD plus a prospective validation cohort of 23 cats with IBD or food-responsive enteropathy. The index combines gastrointestinal signs, endoscopic abnormalities, serum total protein, ALT/ALP activity and serum phosphorus. It is the outcome measure used in both feline MSC studies and is therefore the instrument any PetSmartMeds follow-up must be benchmarked against.
Frecuencia sugerida: Weight, body condition score and muscle condition score at EVERY visit - weight trajectory is the most honest single number in this disease. Recheck 2-4 weeks after any diet change or drug change, and re-evaluate a diet trial at 3 weeks if there has been no improvement. ON CHLORAMBUCIL: CBC before the first dose, then conventionally every 2-4 weeks during induction and every 1-3 months once stable, with a urine dipstick for glucose at each CBC to screen for chlorambucil-associated Fanconi syndrome (clinically silent in 3 of 4 reported cats, and neither polyuria nor polydipsia was noted in any of them). Dosing is held and reassessed on a low neutrophil count, and the human label notes the neutrophil fall can continue for 10 days after the last dose - so a recheck count after holding is not optional. Ask at every visit about twitching, tremors or seizure activity. ON CYCLOPHOSPHAMIDE: CBC on the same principle, with the label's non-administration thresholds (neutrophils <=1,500/mm3, platelets <50,000/mm3) as the floor and nadirs expected in weeks 1-2; add a urinalysis looking for haematuria, and ask at every visit about blood in the urine or straining to urinate. ON PREDNISOLONE: body weight and body condition (dose on lean or ideal weight, and re-check the dose when the weight changes), water intake and urine output, blood or urine glucose on long-term therapy, and thoracic auscultation with a low threshold for re-examining any new tachypnoea. Never an abrupt stop - taper. SERUM COBALAMIN at diagnosis and again 4-6 weeks after starting supplementation, which sits inside the 27-94 day recheck window of the source study. Full FCEAI scoring only at the timepoints where endoscopy and bloodwork are actually being repeated - typically diagnosis and any decision point about changing therapy. Owner check-in weekly during induction, then monthly once stable. Note that the published feline MSC trials used a 2-month and a 6-month recheck, so any comparison to them needs those same timepoints.
Preguntas que puede responder en casa
- How many times did your cat vomit this week? (Count hairballs too.)
- What did the stools look like - firm, soft-but-formed, pudding, or liquid? How many days this week were not normal?
- Is your cat eating more, the same, or less than a month ago - and is it finishing meals?
- What is the weight this week? (A home scale reading to the nearest 100 g is genuinely useful; weight is the number we trust most.)
- Is your cat jumping, playing and grooming as much as usual, or hiding and sleeping more?
- Did you give any treat, table food, flavoured medicine, or another cat's food this week? (Even a small slip can break a diet trial.)
- Have you given your cat anything at all that we did not prescribe - a human medicine, a supplement, or a medicine that was dispensed for another pet?
- Have you missed, doubled, split or stopped any dose? (Tell us plainly - we change the plan around the truth, not around the ideal.)
- If your cat is on chlorambucil or cyclophosphamide: any fever, shivering, pale gums, sudden flatness, twitching or blood in the urine since the last check-in?
- Any yellow tint to the gums, the whites of the eyes, or the skin inside the ears?
- Any new symptom since the last check-in - straining, blood, refusing food for a whole day, or drinking much more? If your cat strained in the litter box, could you tell whether urine was coming out?
Última revisión: 2026-09-20 · Cada afirmación de esta página lleva una fuente que usted puede verificar. Si alguna no se sostiene, díganoslo y la corregiremos. science@petsmartmeds.com
Cree un perfil para su mascota
Cuéntenos qué está enfrentando y el sitio le mostrará solo lo que aplica.